Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's

Phase 2, randomised, open-label trial of levodopa and pramipexole in Parkinson's disease (PD) (3 arms), sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Change in striatal uptake of [123I]ß-CIT from scan 1 to scan 2 at 12 weeks. Started Feb 2004; status: completed.